Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07590934 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
NCT07590934 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 152 participants.
The verdict
NCT07590934, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Interventions
- DRUG AZD9574
- DRUG Docetaxel
- DRUG AZD2265 (FPI-2265)
- DRUG AZD2287 (Imaging agent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2029-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07590934
The ClinicalTrials.gov registry entry for NCT07590934 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AZD9574 is the first listed.
NCT07590934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07590934 about?
NCT07590934 is a clinical study titled "Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
What is the current status of trial NCT07590934?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2026-06-03. Estimated completion is 2029-09-25.
What interventions are being tested in trial NCT07590934?
The interventions under investigation include: AZD9574 (DRUG), Docetaxel (DRUG), AZD2265 (FPI-2265) (DRUG), AZD2287 (Imaging agent) (DRUG).
Who is sponsoring clinical trial NCT07590934?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.